Cutler Group LP Voyager Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	SELL	$5.57 - $7.47 $557 - $747	-100 Reduced 0.96%	10,300 $1,000
Q2 2022 Aug 04, 2022	BUY	$4.82 - $10.09 $29,884 - $62,558	6,200 Added 147.62%	10,400 $4,000
Q1 2022 Apr 14, 2022	BUY	$2.75 - $9.44 $10,450 - $35,872	3,800 Added 950.0%	4,200 $7,000
Q3 2019 Oct 28, 2019	BUY	$16.31 - $28.29 $6,523 - $11,316	400 New	400 $0
Q1 2019 May 10, 2019	SELL	$8.0 - $19.66 $6,400 - $15,728	-800 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$8.59 - $18.05 $13,744 - $28,880	-1,600 Reduced 66.67%	800 $0
Q3 2018 Nov 07, 2018	SELL	$17.11 - $21.74 $1,711 - $2,174	-100 Reduced 4.0%	2,400 $2,000
Q2 2018 Aug 10, 2018	BUY	$16.76 - $23.92 $18,436 - $26,312	1,100 Added 78.57%	2,500 $7,000
Q1 2018 May 11, 2018	SELL	$16.16 - $31.31 $22,624 - $43,834	-1,400 Reduced 50.0%	1,400 $4,000
Q4 2017 Jan 17, 2018	BUY	$12.26 - $25.88 $33,102 - $69,876	2,700 Added 2700.0%	2,800 $3,000
Q3 2017 Oct 17, 2017	BUY	$8.37 - $20.59 $836 - $2,059	100	100 $0

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $219M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.